Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research
24.4.2025 10:00:00 EEST | Business Wire | Press release
Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services (www.oncodesign-services.com), a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink™ technology for preclinical services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424538240/en/
AbYlink™ is a regio-selective bioconjugation technology ideally suited for preparing conjugates for use in therapeutic and non-invasive diagnostic applications. Oncodesign Services will use this cutting-edge technology to prepare antibody chelator conjugates for use in preclinical studies to gain insights into the predictive effectiveness of novel treatment approaches in Molecular Radiotherapy, and particularly Radioimmunotherapy in the context of cancer. A joint poster will be presented at the AACR Annual Meeting 2025 to demonstrate the use of the non-invasive technology in Radioimmunotherapy, targeting animal models bearing HER2+ tumors.
“We have demonstrated the effectiveness of this powerful technology to rapidly and covalently conjugate any off-the-shelf antibody in a single step with an imaging agent. Our strategic collaboration with Oncodesign Services allows broader access to and usage of non-invasive imaging applications and provides an innovative solution to biotech and pharma partners to integrate imagery in the development of new antibody- and ADC-based therapeutics,” commented Frédéric Lévy, Chief Scientific Officer at Debiopharm.
Aidan Synnott, CEO of Oncodesign Services, said, “We are pleased to integrate this cutting-edge technology into our portfolio for our clients. The AbYlink™ technology gives the advantage of generating reproducible batches of bioconjugated antibodies and ADCs that secure specificity and efficacy of targeted radiotherapy.”
About AbYlink™
AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use to prepare diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads.
About Debiopharm Research & Manufacturing
Debiopharm Research & Manufacturing manufactures treatments for prostate cancer, breast cancer and precocious puberty, namely at its Martigny facility, where it employs two hundred people. It is a subsidiary of the pharmaceutical company Debiopharm, headquartered in Lausanne, Switzerland. Debiopharm is an innovative company, devoting over 90% of its resources to innovation and the development of new drugs. Its mission is to develop innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select pharmaceutical commercialization partners to maximize patient access globally.
For more information, please visit: www.debiopharm.com
Follow us on LinkedIn https://www.linkedin.com/company/debiopharminternational/
About Oncodesign Services
Oncodesign Services is a contract research organization specializing in drug discovery and preclinical development. The company works with global biopharma partners to advance therapies in oncology, inflammation and infectious diseases through integrated services in protein sciences, structural biology, medicinal chemistry, pharmaco-imaging, DMPK and in vivo/in vitro pharmacology. Oncodesign Services has European facilities in France and the Netherlands.
More information on the website www.oncodesign-services.com
Follow us on LinkedIn https://www.linkedin.com/company/oncodesign/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424538240/en/
Contacts
Debiopharm Research & Manufacturing Contact:
Dawn Bonine – Head of Communications
Dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
Oncodesign Services Contact:
Nathalie Dubois – Marketing Manager
comms@oncodesign-services.com
Tel.: +33 (0)3 80 78 82 60
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Reports Q3 2026 Results, with Growth in its Specialty Ingredients & Solutions Business and Solos Activity Net Profit and Cashflow from Operating Activities9.11.2026 12:18:00 EET | Press release
Regulatory News: Tsahi Barak, Chairman of the Board and CEO of the Company, commented: "We are pleased to report another quarter of growth across all key operating parameters, alongside an important strategic acquisition. We continue to make substantial investments in production infrastructure, innovation and the recruitment of key talents. We are only beginning to see the fruits of these moves, reflected in the continued profitable growth of our Specialty Ingredients & Solutions (SIS) business and in the acceleration of growth at Solos, alongside moderate growth and improved profitability in our Juice Solutions business during the quarter. The acquisition of BOK that we announced a few days ago is a strategic step that deepens our activity with the wine industry and expands our basket of natural products based on wine-industry by-products, all while maintaining circular economy principles. The move will increase sales turnover, improve profitability and expand the Company’s product an
Logistics Reply named a Leader in the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing9.11.2026 11:00:00 EET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail 2026 Vendor Assessment (doc #US53701926, October 2026) as well as in the IDC MarketScape: Worldwide Warehouse Management for Manufacturing 2026 Vendor Assessment (doc #US53013526, October 2026). The reports evaluate vendors based on strategy and product capabilities, looking at both quantitative and qualitative criteria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109197861/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Warehouse Management for Retail and Manufacturing. LEA ReplyTM is Logistics Reply’s cloud-native warehouse
SWISSto12 passes critical design review of dual-band 5G antennas for UNIVITY satellites9.11.2026 10:00:00 EET | Press release
SWISSto12, a leading enabler of the new space economy, today announced it has passed the Critical Design Review (CDR) for the S- and Ka-band phased array antennas for UNIVITY’s 5G non-terrestrial network (NTN) demonstration satellites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109823601/en/ SWISSto12's S- and Ka-band phased array antennas pass Critical Design Review SWISSto12 is developing two active antennas for UNIVITY: an S-band direct radiating array (DRA) for direct-to-device services, connecting standard 5G phones straight to the satellite, and a Ka-band DRA operating at 26 GHz for broadband services and feeder links. Both are built for 5G NTN applications, allowing one single satellite to carry both broadband and direct-to-device 5G connectivity. These developments are part of UNIVITY's uniShape program, institutionally supported by France 2030 and the French Space Agency (CNES). This dual capability supports
Avanzanite Announces Exclusive Licence Agreement to Commercialise Zemcelpro ® in Europe9.11.2026 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (“Avanzanite” or “Company”) a European pharmaceutical company focused on rare diseases, today announced an exclusive licence agreement with Montreal-based Cordex Biologics, an ExCellThera company (“ExCellThera”), a leader in enhanced blood stem cell therapies, to commercialise Zemcelpro®. Zemcelpro received conditional marketing authorisation from the European Commission on 25 August 2025 for the treatment of adult patients with haematological malignancies requiring an allogeneic haematopoietic stem cell transplant (allo-HSCT) following myeloablative conditioning for whom no other type of suitable donor cells is available. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261108032164/en/ Adam Plich, Co-founder and CEO, Avanzanite Bioscience Under the agreement, Avanzanite will lead commercialisation across 32 countries including the European Economic Area, UK and Switzerland. Avanzanite will become t
Arrow Electronics launches new business Capstone to increase focus on IP&E solutions9.11.2026 08:00:00 EET | Press release
Arrow Electronics, Inc. (NYSE:ARW) today announced the launch of Capstone, a global business dedicated to interconnect, passive and electromechanical (IP&E) products, solutions and services. With Capstone, Arrow creates a focused and specialized go-to-market approach for IP&E as that technology segment becomes more critical for system performance, reliability and supply continuity. Capstone is designed to make IP&E easy to specify, source and scale. Customers will gain the benefit of dedicated IP&E coverage, fast decision-making and broad execution support across the full on-board and off-board electrical system. By operating under a focused brand, Capstone gives customers more specialized support from design-in through production. The result is a strong platform for improving design choices, reducing execution risk and helping customers scale. The launch of Capstone is part of a broader realignment of Arrow’s global components business, moving from a geography operating model to a tec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom